---
document_datetime: 2025-11-23 07:23:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/regkirona.html
document_name: regkirona.html
version: success
processing_time: 0.2262156
conversion_datetime: 2025-12-29 19:26:20.177312
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Regkirona

[RSS](/en/individual-human-medicine.xml/67509)

##### Withdrawn

This medicine's authorisation has been withdrawn

regdanvimab

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Regkirona](#news-on)
- [Related content](#related-content-72348)
- [More information on Regkirona](#related-medicines)

- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 14 April 2025, the European Commission withdrew the marketing authorisation for Regkirona (regdanvimab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Celltrion Healthcare Hungary Kft., which notified the European Commission of its decision to permanently discontinue the marketing of Regkirona for commercial reasons.

Regkirona was granted marketing authorisation in the EU on 12 November 2021 for the treatment of COVID-19. The marketing authorisation was initially valid for a 5-year period.

Regkirona : EPAR - Medicine overview

Reference Number: EMA/629707/2021

English (EN) (178.37 KB - PDF)

**First published:** 12/11/2021

**Last updated:** 24/04/2025

[View](/en/documents/overview/regkirona-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-931)

български (BG) (229.29 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/bg/documents/overview/regkirona-epar-medicine-overview_bg.pdf)

español (ES) (177 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/es/documents/overview/regkirona-epar-medicine-overview_es.pdf)

čeština (CS) (220.5 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/cs/documents/overview/regkirona-epar-medicine-overview_cs.pdf)

dansk (DA) (176.79 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/da/documents/overview/regkirona-epar-medicine-overview_da.pdf)

Deutsch (DE) (185.21 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/de/documents/overview/regkirona-epar-medicine-overview_de.pdf)

eesti keel (ET) (157.83 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/et/documents/overview/regkirona-epar-medicine-overview_et.pdf)

ελληνικά (EL) (236.68 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/el/documents/overview/regkirona-epar-medicine-overview_el.pdf)

français (FR) (180.31 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/fr/documents/overview/regkirona-epar-medicine-overview_fr.pdf)

hrvatski (HR) (211.6 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/hr/documents/overview/regkirona-epar-medicine-overview_hr.pdf)

italiano (IT) (173.23 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/it/documents/overview/regkirona-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (218.53 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/lv/documents/overview/regkirona-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (207.48 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/lt/documents/overview/regkirona-epar-medicine-overview_lt.pdf)

magyar (HU) (210.53 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/hu/documents/overview/regkirona-epar-medicine-overview_hu.pdf)

Malti (MT) (216.41 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/mt/documents/overview/regkirona-epar-medicine-overview_mt.pdf)

Nederlands (NL) (182.98 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/nl/documents/overview/regkirona-epar-medicine-overview_nl.pdf)

polski (PL) (218.78 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/pl/documents/overview/regkirona-epar-medicine-overview_pl.pdf)

português (PT) (175.38 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/pt/documents/overview/regkirona-epar-medicine-overview_pt.pdf)

română (RO) (208.03 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/ro/documents/overview/regkirona-epar-medicine-overview_ro.pdf)

slovenčina (SK) (219.21 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/sk/documents/overview/regkirona-epar-medicine-overview_sk.pdf)

slovenščina (SL) (207.3 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/sl/documents/overview/regkirona-epar-medicine-overview_sl.pdf)

Suomi (FI) (173.09 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/fi/documents/overview/regkirona-epar-medicine-overview_fi.pdf)

svenska (SV) (171.16 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/sv/documents/overview/regkirona-epar-medicine-overview_sv.pdf)

Regkirona : EPAR - Risk-management-plan

English (EN) (2.18 MB - PDF)

**First published:** 12/11/2021

**Last updated:** 24/04/2025

[View](/en/documents/rmp/regkirona-epar-risk-management-plan_en.pdf)

## Product information

Regkirona : EPAR - Product information

English (EN) (1.14 MB - PDF)

**First published:** 12/11/2021

**Last updated:** 24/04/2025

[View](/en/documents/product-information/regkirona-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-519)

български (BG) (1.43 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/bg/documents/product-information/regkirona-epar-product-information_bg.pdf)

español (ES) (1.17 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/es/documents/product-information/regkirona-epar-product-information_es.pdf)

čeština (CS) (1.28 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/cs/documents/product-information/regkirona-epar-product-information_cs.pdf)

dansk (DA) (1.14 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/da/documents/product-information/regkirona-epar-product-information_da.pdf)

Deutsch (DE) (1.22 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/de/documents/product-information/regkirona-epar-product-information_de.pdf)

eesti keel (ET) (1.12 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/et/documents/product-information/regkirona-epar-product-information_et.pdf)

ελληνικά (EL) (1.51 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/el/documents/product-information/regkirona-epar-product-information_el.pdf)

français (FR) (1.25 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/fr/documents/product-information/regkirona-epar-product-information_fr.pdf)

hrvatski (HR) (1.4 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/hr/documents/product-information/regkirona-epar-product-information_hr.pdf)

íslenska (IS) (1.18 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/is/documents/product-information/regkirona-epar-product-information_is.pdf)

italiano (IT) (1.31 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/it/documents/product-information/regkirona-epar-product-information_it.pdf)

latviešu valoda (LV) (1.44 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/lv/documents/product-information/regkirona-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.41 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/lt/documents/product-information/regkirona-epar-product-information_lt.pdf)

magyar (HU) (1.43 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/hu/documents/product-information/regkirona-epar-product-information_hu.pdf)

Malti (MT) (1.49 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/mt/documents/product-information/regkirona-epar-product-information_mt.pdf)

Nederlands (NL) (1.17 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/nl/documents/product-information/regkirona-epar-product-information_nl.pdf)

norsk (NO) (1.18 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/no/documents/product-information/regkirona-epar-product-information_no.pdf)

polski (PL) (1.43 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/pl/documents/product-information/regkirona-epar-product-information_pl.pdf)

português (PT) (1.2 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/pt/documents/product-information/regkirona-epar-product-information_pt.pdf)

română (RO) (1.47 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/ro/documents/product-information/regkirona-epar-product-information_ro.pdf)

slovenčina (SK) (1.35 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/sk/documents/product-information/regkirona-epar-product-information_sk.pdf)

slovenščina (SL) (1.37 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/sl/documents/product-information/regkirona-epar-product-information_sl.pdf)

Suomi (FI) (1.28 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/fi/documents/product-information/regkirona-epar-product-information_fi.pdf)

svenska (SV) (1.19 MB - PDF)

**First published:**

12/11/2021

**Last updated:**

24/04/2025

[View](/sv/documents/product-information/regkirona-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0016 25/08/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Regkirona : EPAR - All authorised presentations

English (EN) (72.04 KB - PDF)

**First published:** 16/11/2021

**Last updated:** 24/04/2025

[View](/en/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-760)

български (BG) (87.95 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/bg/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_bg.pdf)

español (ES) (73.53 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/es/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.09 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/cs/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (75.02 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/da/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (75.8 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/de/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (70.5 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/et/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (83.92 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/el/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_el.pdf)

français (FR) (74.66 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/fr/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (74.45 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/hr/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (73.69 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/is/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_is.pdf)

italiano (IT) (74.1 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/it/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (79.42 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/lv/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (75.85 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/lt/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (76.13 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/hu/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (106.43 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/mt/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (73.63 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/nl/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (75.07 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/no/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_no.pdf)

polski (PL) (78.66 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/pl/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_pl.pdf)

português (PT) (75.9 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/pt/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_pt.pdf)

română (RO) (75.71 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/ro/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (78.29 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/sk/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (73.43 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/sl/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (69.11 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/fi/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (72.06 KB - PDF)

**First published:**

16/11/2021

**Last updated:**

24/04/2025

[View](/sv/documents/all-authorised-presentations/regkirona-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Regkirona Active substance regdanvimab International non-proprietary name (INN) or common name regdanvimab Therapeutic area (MeSH) COVID-19 virus infection Anatomical therapeutic chemical (ATC) code J06BD06

### Pharmacotherapeutic group

Immune sera and immunoglobulins

### Therapeutic indication

Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

## Authorisation details

EMA product number EMEA/H/C/005854 Marketing authorisation holder

Celltrion Healthcare Hungary Kft.

1062 Budapest

Opinion adopted 11/11/2021 Marketing authorisation issued 12/11/2021 Withdrawal of marketing authorisation 14/04/2025 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Regkirona : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (345.09 KB - PDF)

**First published:** 13/12/2021

**Last updated:** 30/10/2024

[View](/en/documents/procedural-steps-after/regkirona-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Regkirona : EPAR - Public assessment report

Adopted

Reference Number: EMA/679271/2021

English (EN) (12.11 MB - PDF)

**First published:** 30/11/2021

**Last updated:** 24/04/2025

[View](/en/documents/assessment-report/regkirona-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Regkirona

Adopted

Reference Number: EMA/CHMP/629422/2021

English (EN) (158.88 KB - PDF)

**First published:** 11/11/2021

**Last updated:** 24/04/2025

[View](/en/documents/smop-initial/chmp-summary-opinion-regkirona_en.pdf)

#### News on Regkirona

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2024) 13/12/2024

[ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2](/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2) 09/12/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

[COVID-19: EMA recommends authorisation of two monoclonal antibody medicines](/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines) 11/11/2021

#### Related content

- [Emergency Task Force (ETF) documents: COVID-19](/en/committees/working-parties-other-groups/emergency-task-force-etf/emergency-task-force-etf-recommendations#covid-19-66890)

#### More information on Regkirona

- [EMEA-002961-PIP01-21-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002961-pip01-21-m02)

**This page was last updated on** 24/04/2025

## Share this page

[Back to top](#main-content)